Custom Search by Tirgan.com

Home    Content    services

Cladribine (Leustatin)

Cladribine is one of the newest chemotherapy drugs which has been used for a few years. Cladribine is a white powder which, when prepared for use, becomes a clear, colorless liquid. It is administered by intravenous route only. It is most commonly used in treatment of the following cancers:

• Hairy cell leukemia

• Low grade lymphomas

• Waldenström's Macroglobulinemia

The type and extent of a cancer will determine the method and schedule of administration of this drug. This decision is made by the medical oncologist. Cladribine is normally given daily for seven consecutive days as a continuous intravenous infusion and repeated every four weeks. Proper dosage and schedule is still being studied.

Side Effects:

The degree and severity of the side effects depend on the amount and schedule of the administration of Cladribine. Following are some of the most common and significant ill effects:

• Low white blood counts

• Low platelet count

• Anemia

• Fever

• Skin rash

It is imperative that a patient relay any side effects or problems to his/her medical oncologist.